Protagonist/J&J Explore Autoimmune FRONTIER With Positive Psoriasis Results
Executive Summary
While full data are not yet available, JNJ-2113 would be the first oral drug against IL-23R, setting up for potential competition against oral TYK2 and IL-17-targeting drugs.
You may also be interested in...
Protagonist Weaves Positive Story From Mixed Phase II Data In Ulcerative Colitis
The company is pushing ahead into Phase III development with the lower dose of an oral drug for ulcerative colitis, even though a Phase II study missed the primary endpoint.
Unity’s UBX1325 Faces Uncertain Path Forward In AMD, But DME Still Looks Promising
The company said the Phase II ENVISION study of the drug in wet age-related macular degeneration did not show non-inferiority to Eylea, leaving it with an uncertain path forward in that indication.
Generation Bio’s LNP DNA-Delivery Platform Gets Big Boost From Moderna
The company aims to deliver DNA via lipid nanoparticles as well as delivering LNPs systemically to tissues beyond the liver and spleen, which the CEO called a “frontier” in an interview.